KR20120114235A - 알파-1 프로테이나제 억제제에 대한 조성물, 방법 및 키트 - Google Patents

알파-1 프로테이나제 억제제에 대한 조성물, 방법 및 키트 Download PDF

Info

Publication number
KR20120114235A
KR20120114235A KR1020127013706A KR20127013706A KR20120114235A KR 20120114235 A KR20120114235 A KR 20120114235A KR 1020127013706 A KR1020127013706 A KR 1020127013706A KR 20127013706 A KR20127013706 A KR 20127013706A KR 20120114235 A KR20120114235 A KR 20120114235A
Authority
KR
South Korea
Prior art keywords
composition
api
amino acid
alanine
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127013706A
Other languages
English (en)
Korean (ko)
Inventor
지안신 궈
앤터니 클로스
브렛 콜드렌
데보라 바네트
마크 매닝
Original Assignee
그리폴스 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43970713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20120114235(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 그리폴스 테라퓨틱스 인코포레이티드 filed Critical 그리폴스 테라퓨틱스 인코포레이티드
Publication of KR20120114235A publication Critical patent/KR20120114235A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020127013706A 2009-11-03 2010-11-02 알파-1 프로테이나제 억제제에 대한 조성물, 방법 및 키트 Ceased KR20120114235A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25771109P 2009-11-03 2009-11-03
US61/257,711 2009-11-03

Publications (1)

Publication Number Publication Date
KR20120114235A true KR20120114235A (ko) 2012-10-16

Family

ID=43970713

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127013706A Ceased KR20120114235A (ko) 2009-11-03 2010-11-02 알파-1 프로테이나제 억제제에 대한 조성물, 방법 및 키트

Country Status (19)

Country Link
US (2) US20130131192A1 (cg-RX-API-DMAC7.html)
EP (1) EP2496246B1 (cg-RX-API-DMAC7.html)
JP (2) JP2013510158A (cg-RX-API-DMAC7.html)
KR (1) KR20120114235A (cg-RX-API-DMAC7.html)
CN (1) CN102655876B (cg-RX-API-DMAC7.html)
AU (1) AU2010315325B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012010392B8 (cg-RX-API-DMAC7.html)
CA (1) CA2779369C (cg-RX-API-DMAC7.html)
CL (1) CL2012001159A1 (cg-RX-API-DMAC7.html)
ES (1) ES2679819T3 (cg-RX-API-DMAC7.html)
HU (1) HUE039240T2 (cg-RX-API-DMAC7.html)
IL (1) IL219485A (cg-RX-API-DMAC7.html)
MX (1) MX2012005132A (cg-RX-API-DMAC7.html)
NZ (1) NZ599783A (cg-RX-API-DMAC7.html)
PL (1) PL2496246T3 (cg-RX-API-DMAC7.html)
PT (1) PT2496246T (cg-RX-API-DMAC7.html)
RU (1) RU2555332C2 (cg-RX-API-DMAC7.html)
TR (1) TR201809898T4 (cg-RX-API-DMAC7.html)
WO (1) WO2011056793A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014007127A2 (pt) * 2011-12-30 2017-04-04 Grifols Sa métodos para retardar o início ou diminuir a progressão de um ou mais sintomas, para retardar o início ou a progressão de um ou mais sintomas, para identificar um indivíduo em necessidade de terapia de manutenção de a1pi, e para identificar indivíduos com risco elevado para exacerbações pulmonares, uso de a1pi, aparelho e meio para a administração aerossolizada de a1pi para a inalação, e, kit
IL267520B2 (en) * 2016-12-22 2023-09-01 Kamada Ltd Dry powder composition of alpha-1 antitrypsin
WO2018132874A1 (en) * 2017-01-19 2018-07-26 Csl Limited Method of preventing an immune response with alpha- 1 anti-trypsin
IL267923B2 (en) 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
US11566031B2 (en) * 2019-03-04 2023-01-31 Tae Life Sciences, Llc Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof
MX2022010087A (es) 2020-02-25 2022-09-02 Grifols Worldwide Operations Ltd Procedimiento para obtener un inhibidor de proteinasa alfa-1.

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5029005B2 (cg-RX-API-DMAC7.html) * 1972-05-08 1975-09-19
JPS51118819A (en) * 1975-04-08 1976-10-19 Green Cross Corp:The A process for preparing heat stable antitrypsin
JPS597693B2 (ja) 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
US4337242A (en) 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4623717A (en) 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
US5218091A (en) 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
JP2599585B2 (ja) 1984-06-19 1997-04-09 トランスジ−ン ソシエテ アノニム ヒトα▲下１▼−アンチトリプシン誘導体及びその製造法
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE3901917A1 (de) 1989-01-24 1990-07-26 Behringwerke Ag Mutanten von humanem antithrombin iii
GB8913183D0 (en) 1989-06-08 1989-07-26 Central Blood Lab Authority Chemical products
US5079336A (en) 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5032405A (en) 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
JP3479539B2 (ja) 1992-04-10 2003-12-15 エーザイ株式会社 ヒトアンチトロンビンｉｉｉ変異体
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5561115A (en) 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
KR20010052345A (ko) 1998-05-12 2001-06-25 수잔 씨 복 인간 항트롬빈 3 및 그에 관련된 방법
CN100553678C (zh) 1999-02-22 2009-10-28 巴克斯特国际有限公司 新的无白蛋白的因子ⅷ制剂
WO2000051624A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methods and compositions useful in inhibiting apoptosis
US20040157911A1 (en) 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
AU2001271021A1 (en) 2000-07-05 2002-01-14 Japan As Represented By Secretary Of Osaka University Process for producing glycoprotein
WO2003035051A2 (en) * 2001-10-19 2003-05-01 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
US20030235555A1 (en) 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
US7777006B2 (en) * 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
PT1664123E (pt) 2003-09-22 2008-07-16 Kamada Ltd Preparação em larga escala de um inibidor da alfa-1 proteinase e sua utilização
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
WO2005049801A2 (en) 2003-11-14 2005-06-02 Arriva Pharmaceuticals, Inc. Dry protein formulation
SI1684719T1 (sl) 2003-11-14 2012-07-31 Baxter Int Sestavki alfa antitripsina in postopki zdravljenja ob uporabi takih sestavkov
BRPI0509117A (pt) 2004-03-04 2007-08-28 Wyeth Corp método de liofilização para melhorar a cristalização de excipientes
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
BRPI0618893A2 (pt) 2005-11-22 2011-09-13 Wyeth Corp formulações de proteìna de fusão de imunoglobulina
MX2008010173A (es) 2006-02-09 2009-02-12 Kamada Ltd Antitripsina alfa-i para tratar episodios de exacerbacion de enfermedades pulmonares.
JP5810091B2 (ja) 2009-11-24 2015-11-11 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 凍結乾燥方法、組成物、及びキット

Also Published As

Publication number Publication date
JP2013510158A (ja) 2013-03-21
CL2012001159A1 (es) 2012-09-14
CA2779369A1 (en) 2011-05-12
BR112012010392A2 (pt) 2016-07-12
AU2010315325A1 (en) 2012-06-07
EP2496246A2 (en) 2012-09-12
PL2496246T3 (pl) 2018-09-28
MX2012005132A (es) 2012-07-25
RU2012122793A (ru) 2013-12-10
TR201809898T4 (tr) 2018-07-23
PT2496246T (pt) 2018-07-31
JP6030201B2 (ja) 2016-11-24
US9616126B2 (en) 2017-04-11
AU2010315325B2 (en) 2014-11-27
US20130131192A1 (en) 2013-05-23
WO2011056793A2 (en) 2011-05-12
CA2779369C (en) 2018-06-19
IL219485A (en) 2017-06-29
ES2679819T3 (es) 2018-08-31
BR112012010392B1 (pt) 2021-01-05
CN102655876B (zh) 2015-07-15
HUE039240T2 (hu) 2018-12-28
JP2015221835A (ja) 2015-12-10
IL219485A0 (en) 2012-06-28
ES2679819T8 (es) 2019-01-22
EP2496246B1 (en) 2018-06-27
EP2496246A4 (en) 2013-03-27
BR112012010392B8 (pt) 2021-05-25
RU2555332C2 (ru) 2015-07-10
WO2011056793A3 (en) 2011-09-29
NZ599783A (en) 2013-10-25
US20160106843A1 (en) 2016-04-21
CN102655876A (zh) 2012-09-05

Similar Documents

Publication Publication Date Title
US9616126B2 (en) Composition, method, and kit for alpha-1 proteinase inhibitor
KR101880905B1 (ko) 안정한 수성 ｍｉａ／ｃｄ－ｒａｐ 제제
JP4119407B2 (ja) 凍結乾燥されたアルブミン非含有の組換え人血液凝固第８因子製剤
PT2720710E (pt) Formulações liofilizadas de fgf-18
WO1997002832A1 (fr) Preparations lyophilisees de hgf
US12144849B2 (en) Composition comprising highly-concentrated Alpha1 proteinase inhibitor and method for obtaining thereof
KR101492511B1 (ko) Ｈｇｆ 제제
AU2020311050B2 (en) Stable formulations of recombinant proteins
WO2022132636A1 (en) High concentration formulations of anti-csf1 and anti-csf1r antibodies
JP5265514B2 (ja) Ｈｇｆ製剤
RU2776108C2 (ru) Лиофилизированный состав на основе hgf
EA047252B1 (ru) Стабильные составы рекомбинантных белков
HK40026929A (en) Composition comprising highly-concentrated alpha-1 proteinase inhibitor and method for obtaining thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120525

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131004

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150504

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151126

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150504

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20151126

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20150622

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20160122

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20151222

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20151126

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150622

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20150504

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20160219

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20160122

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20151126

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2016101000968

Request date: 20160219

J301 Trial decision

Free format text: TRIAL NUMBER: 2016101000968; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20160219

Effective date: 20170714

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20170714

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20160219

Decision date: 20170714

Appeal identifier: 2016101000968